CYAD Celyad Oncology SA

EBR · BE · Healthcare · Biotechnology · celyad.com

0.2250EUR+2.27%Mkt Cap: 18.31M $P/E: 11.254d ago

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap18.31M USD

Enterprise Value10.57M USD

Revenue (TTM)7.61K USD

Gross Profit14.13K USD

Net Income (TTM)902.17K USD

Revenue/Share0.00 EUR

Last Price0.2250 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees4

CountryBE

SectorHealthcare

IndustryBiotechnology

ISINBE0974260896

Valuation

P/E (Trailing)11.25

P/E (Forward)0.34

PEG—

EV/EBITDA12.55

EV/Revenue1389.52

P/S2353.47

P/B4.07

EPS (TTM)0.02

EPS (Forward)0.64

52W Range

0.160013% of range0.6500

52W High0.6500 EUR

52W Low0.1600 EUR

Profitability

Gross Margin61.90%

Oper. Margin13300.00%

EBITDA Margin11071.43%

Profit Margin3952.38%

ROE34.06%

ROA19.31%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-7.50M USD

CapEx (TTM)—

FCF Margin-16280.36%

FCF Yield-6.76%

Net Debt-131.52K USD

Net Debt/EBITDA-0.16

Balance Sheet

Debt/Equity0.00

Current Ratio0.94

Quick Ratio0.91

Book Value/Sh0.05 EUR

Cash/Share0.0030 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.74.88M

Float14.15M

Insiders10.28%

Institutions55.49%

Technical

SMA 500.2608 (-13.7%)

SMA 2000.2713 (-17.1%)

Beta1.21

S&P 52W Chg13.94%

Avg Vol (30d)12.35K

Avg Vol (10d)13.01K

Technical Indicators

RSI (14)42.3

MACD-0.0103

MACD Signal-0.0082

MACD Hist.-0.0021

BB Upper0.2781 EUR

BB Middle0.2435 EUR

BB Lower0.2090 EUR

BB Width28.34%

ATR (14)0.0161 EUR

Vol Ratio (20d)0.58x